FOR IMMEDIATE RELEASE:
SilcsBio Joins with NIST and Pharma Partner In Validating SILCS Technology for Biologics Formulation
Scientific collaboration demonstrates effective computational method for stabilizing biologic therapeutics such as antibodies
December 16, 2020, Baltimore, MD – SilcsBio, LLC, a technology company that develops and markets software and services for structure-based drug design, today announced members of its scientific and research team have published an article in Molecular Pharmaceutics in conjunction with scientists with the US National Institute of Standards and Technology (NIST) and a related pharmaceutical partner.
“There are a lot of promising antibody therapies that struggle to get to human trials because the antibodies can’t be stabilized in solution for injection, so we set out to develop a new method for solving that problem,” said Alex Meltzer, PhD, Drug Development Strategist with SilcsBio. “This work lays the foundation for rapid, cost effective biologic formulation design”.
The article, titled “Computational Characterization of Antibody−Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach,” highlights the combination of the accuracy of the SILCS ligand docking- which has been used by industrial drug developers for small molecule therapeutics for over 8 years- and protein-protein interaction technologies. The result is a new SILCS-Biologics approach to allow for comprehensive mapping of the binding locations and affinities of excipients on the entire surface of protein therapeutics including monoclonal antibodies (mAb).
In addition, the authors show the application of the SILCS-Biologics approach (software now available as Early Access to select users) to the NIST mAb identified calculated SILCS metrics for a collection of 8 excipients that yield strong correlations with experimental data with viscosity at high protein concentrations and with relative protein stability. The results indicate the utility of the SILCS-Biologics technology in facilitating the rational selection of excipients during the biologics formulation process.
NIST, a nonregulatory agency of the U.S. Department of Commerce, promotes U.S. innovation and industrial competitiveness by advancing measurement science, standards and technology in ways that enhance economic security and improve our quality of life. Learn more: www.NIST.gov
SilcsBio, launched in Baltimore, MD in 2013, provides commercial software and consultative services for structure-based drug design for customers in the US, Europe and Japan. SilcsBio’s proprietary technology is based on licensed intellectual property developed by Dr. Alex MacKerell at the University of Maryland, Baltimore where he is the Grollman-Glick Professor of Pharmaceutical Sciences and Director of the Computer-Aided Drug Design Center. Learn more: www.silcsbio.com